Karolinska Institutet and AstraZeneca has recruited Professor Bo Angelin to lead the Integrated Cardio Metabolic Centre (ICMC).
Bo Angelin is a Professor of Clinical Metabolism at Karolinska Institutet and a senior consultant at the Department of Endocrinology, Metabolism & Diabetes at Karolinska University Hospital. He is an internationally renowned researcher in the field of lipid metabolism. Recently he was awarded a grant from the Knut and Alice Wallenberg Foundation for identifying new mechanisms responsible for congenital blood lipid disorders with a high risk of early cardiovascular disease.
“These research areas are very important, and the ICMC links in to my own research,” said Professor Angelin in a press release. “It will be truly exciting to take on this task, and I see good opportunities to tie the very best scientists to us.”
Professor Angelin will over the coming three years also be leading some thirty or so scientists from Karolinska Institutet and AstraZeneca, who will be conducting clinical and pre-clinical studies together in order to identify the mechanisms behind cardiovascular disease and metabolic diseases, and to find new target molecules for treatment. During the first five years, AstraZeneca will be contributing a total of USD 100 million (approximately SEK 650 million). The ICMC will be located on Karolinska Institutet’s Huddinge campus.